Blenrep, a first-in-class anti-BCMA ADC has the potential to be a new standard of care as early as first relapse where additional effective and accessible options are needed.1,2,3 Sixth major approval for Blenrep combinations with applications under review in all major markets. GSK plc (LSE/NYSE: GSK) has announced the marketing authorisation of Blenrep by the European Commission. Blenrep is now approved in the European Union (EU) for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus…